N4 Pharma bears more good news on its Nuvec particles

(Sharecast News) - Specialist pharmaceutical company N4 Pharma updated on the latest key research findings for its 'Nuvec' delivery system on Wednesday.The AIM-traded firm had announced on 29 October that research undertaken to then indicated that Nuvec particles themselves had demonstrated a "clear adjuvant effect" to help deliver a level of immune response for both messenger RNA (mRNA) and plasmid DNA (pDNA) , encoded with the standard test antigen Ovalbumin (OVA).It said on Wednesday taht it had now undertaken further analysis of its pDNA OVA findings, and demonstrated that the immune response observed was sufficient to have produced strong levels of antibodies specific for OVA.A strong level of antibody production was essential for a vaccine to deliver immunity, N4 Pharma explained.It said the levels of antibodies produced were greater than those of in 'vivo-jetPEI', an industry standard used to deliver pDNA-OVA in pre clinical studies.Additionally, it said that assessing the detailed classes of antibodies produced showed that Nuvec delivered a "strong, robust level" of the specific antibodies needed for effective oncology and virology vaccines.The company had also now manufactured one new large batch of particles for its EUNCL and Adelaide research work, it explained, and would be shipping particles from that batch to the relevant parties shortly.N4 Pharma said the research for those programmed would now commence fully in January.EUNCL was expected to deliver results towards the end of the third quarter of 2019, with the first part of the Adelaide work to take four weeks and start in the new year, with results expected during the first quarter."These results are once again another positive step forward for our Nuvec delivery platform," said chief executive officer Nigel Theobald."The data now shows Nuvec® is capable of producing specific and relevant strong levels of antibodies required for the development of vaccines and cancer treatments."Theobald said the company would continue to provide updates as it added to its "already encouraging" data package to aid its commercial collaboration discussions."The production of a robust data package using the test antigen Ovalbumin provides compelling evidence of the potential for Nuvec to be an effective delivery system for a potential partner's specific DNA or RNA antigen."